Biovail To List On The New York Stock Exchange.TORONTO--(BUSINESS WIRE)--Nov. 25, 1996--Biovail Corporation International (AMEX AMEX See: American Stock Exchange , TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :BVF) today announced that it has been approved for listing of its common stock on the New York Stock Exchange New York Stock Exchange (NYSE) World's largest marketplace for securities. The exchange began as an informal meeting of 24 men in 1792 on what is now Wall Street in New York City. (NYSE NYSE See: New York Stock Exchange ). The Company expects its shares will begin trading on the NYSE on Thursday, December 12, 1996, under the symbol "BVF". Currently, Biovail has approximately 25.4 million common shares outstanding, which are traded on the American Stock Exchange American Stock Exchange (AMEX) Stock exchange in the U.S. Originally known as “the Curb,” it began as an outdoor marketplace in New York City c. 1850. It moved indoors to its present location in the Wall Street area in 1921. and the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. under the symbol "BVF". Eugene Melnyk, Chairman of the Board, commented, "Given the significant growth Biovail has experienced in the past year and the significant opportunities we foresee going forward, we believe the New York Stock Exchange will offer our shareholders the best trading environment for our common stock. With the New York Stock Exchange being the world's largest equity marketplace, we anticipate greater visibility, sponsorship and liquidity for our stock as well as for our current and prospective shareholders." Biovail Corporation International is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration and manufacture of drug products utilizing advanced drug delivery technologies. CONTACT: Biovail Corporation International Eugene Melnyk Chairman of the Board Bob Podruzny Chief Financial Officer (416) 285-6000 or Investor Relations: Donna Stein/ Dan Durkin/Cindy Hintelmann Press: Michael McMullan Morgen-Walke Associates (212) 850-5600 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion